New Advances in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives

Join us for this expert-led educational program featuring live, interactive Webinars about the current guidelines and new treatment advances for your patients with relapsed/refractory multiple myeloma and then download the slides and listen to the podcast of frequently asked questions!
Shaji Kumar, MD
Program Director
Natalie S. Callander, MD

Podcast

In this podcast episode, listen to myeloma experts Natalie S. Callander, MD, and Shaji Kumar, MD, respond to audience questions from a live CCO Webinar discussing current guidelines and treatment advances for patients with relapsed/refractory multiple myeloma.

Shaji Kumar, MD
Program Director
Natalie S. Callander, MD
Released: September 1, 2020

Downloadable Slidesets

Downloadable slides with expert analysis of treatment strategies for heavily pretreated relapsed/refractory multiple myeloma.

Shaji Kumar, MD
Program Director
Released: June 25, 2020

Downloadable slides with expert analysis of investigational agents and combinations for heavily pretreated relapsed/refractory multiple myeloma

Natalie S. Callander, MD Released: June 25, 2020

On-Demand Webcast

In this interactive, on-demand Webcast, hematology experts review the current guidelines and new treatment advances for patients with relapsed/refractory multiple myeloma and discuss patient cases and new data from the 2020 ASCO Virtual Scientific Meeting.

Shaji Kumar, MD
Program Director
Natalie S. Callander, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 14, 2020 Expired: September 13, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline LLC
Sanofi Genzyme Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue